These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16115187)

  • 41. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
    Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
    Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.
    Hutchison AJ; Maes B; Vanwalleghem J; Asmus G; Mohamed E; Schmieder R; Backs W; Jamar R; Vosskühler A
    Nephron Clin Pract; 2006; 102(2):c61-71. PubMed ID: 16224198
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis.
    Zhai CJ; Yang XW; Sun J; Wang R
    Int Urol Nephrol; 2015 Mar; 47(3):527-35. PubMed ID: 25399356
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Calciphylaxis responsive to lanthanum carbonate (FOSRENOL) therapy.
    Chan MR; Yevzlin AS; Hinshaw M; Jaffery JB
    WMJ; 2008 Nov; 107(7):335-8. PubMed ID: 19180873
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review.
    Zhang C; Wen J; Li Z; Fan J
    BMC Nephrol; 2013 Oct; 14():226. PubMed ID: 24134531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J; Piecha G; Kokot F; Wiecek A
    J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.
    Guo H; Zhang X; Tang S; Zhang S
    Ren Fail; 2013; 35(10):1455-64. PubMed ID: 23992043
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
    Behets GJ; Dams G; Vercauteren SR; Damment SJ; Bouillon R; De Broe ME; D'Haese PC
    J Am Soc Nephrol; 2004 Aug; 15(8):2219-28. PubMed ID: 15284308
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure.
    Damment S; Secker R; Shen V; Lorenzo V; Rodriguez M
    Nephrol Dial Transplant; 2011 Jun; 26(6):1803-12. PubMed ID: 21098011
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
    Savica V; Calò LA; Monardo P; Santoro D; Bellinghieri G
    Nephrol Dial Transplant; 2006 Aug; 21(8):2065-8. PubMed ID: 16766546
    [No Abstract]   [Full Text] [Related]  

  • 52. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
    Hutchison AJ; Speake M; Al-Baaj F
    Nephrol Dial Transplant; 2004 Jul; 19(7):1902-6. PubMed ID: 15199195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic use of the phosphate binder lanthanum carbonate.
    Barton Pai A; Conner TA; McQuade CR
    Expert Opin Drug Metab Toxicol; 2009 Jan; 5(1):71-81. PubMed ID: 19236230
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA; Burke SK; Dillon MA
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
    Hutchison AJ; Laville M;
    Nephrol Dial Transplant; 2008 Nov; 23(11):3677-84. PubMed ID: 18577536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
    Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
    Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lanthanum carbonate.
    Swainston Harrison T; Scott LJ
    Drugs; 2004; 64(9):985-96; discussion 997-8. PubMed ID: 15101790
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate.
    Hutchison AJ; Maes B; Vanwalleghem J; Asmus G; Mohamed E; Schmieder R; Backs W; Jamar R; Vosskuhler A
    Nephron Clin Pract; 2005; 100(1):c8-19. PubMed ID: 15809508
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Introduction to lanthanum carbonate: pharmacology, safety and tolerability].
    Rodríguez Portillo M
    Nefrologia; 2008; 28 Suppl 5():7-10. PubMed ID: 18847413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia].
    Laville M
    Nephrol Ther; 2011 Jun; 7(3):154-61. PubMed ID: 21247818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.